Filing Flows › 8-K events › 60 Degrees Pharmaceuticals
60 Degrees Pharmaceuticals: entry into a material definitive agreement
Form 8-K filed Nov 6, 2026 · items 1.01, 3.02
What the filing says
On November 5, 2026, 60 Degrees Pharmaceuticals, Inc. (the “Company”) entered into inducement offer letter agreements (the “Inducement Letters”) with certain holders (the “Holders”) of certain existing warrants to purchase up to an aggregate of 584,492 shares of the Company’s common stock, par value $0.0001 per share (
Read the filing on SEC EDGAR →
What usually followsAcross 23,525 8-Ks reporting Item 1.01 (material definitive agreement) in our universe, the stock's median move the next session was 0.0% (typical size ±1.4%, up 51% of the time); over the following 21 sessions, +1.0%. Item 3.02: +0.1% next session across 2,750. Every item ranked →
What this kind of filing means
Item 1.01 — Entry into a material definitive agreement. A material agreement is one the company considers important enough to disclose within four business days: a merger agreement, a large supply or customer contract, a credit agreement or a licence. The terms often move the company’s outlook more than a quarter’s results.
60 Degrees Pharmaceuticals at a glance
60 Degrees Pharmaceuticals, Q2 2026: revenue $208K (+106% year over year). The chart follows the revenue to costs, profit and cash.
60 Degrees Pharmaceuticals: every quarter, Q/Q and Y/Y, holders and guidance →
60 Degrees Pharmaceuticals’s other material 8-Ks
- Oct 27, 2026 — FDA decisions 60 Degrees Pharmaceuticals Announces Clinical Improvement and Negative PCR Results in All Completed
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.